JPWO2020069322A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020069322A5 JPWO2020069322A5 JP2021517348A JP2021517348A JPWO2020069322A5 JP WO2020069322 A5 JPWO2020069322 A5 JP WO2020069322A5 JP 2021517348 A JP2021517348 A JP 2021517348A JP 2021517348 A JP2021517348 A JP 2021517348A JP WO2020069322 A5 JPWO2020069322 A5 JP WO2020069322A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- haloalkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 74
- 150000001875 compounds Chemical class 0.000 claims description 68
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 34
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 206010015037 epilepsy Diseases 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 208000014644 Brain disease Diseases 0.000 claims description 15
- 208000032274 Encephalopathy Diseases 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 230000001037 epileptic effect Effects 0.000 claims description 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 206010010904 Convulsion Diseases 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 201000007547 Dravet syndrome Diseases 0.000 claims description 6
- 208000024658 Epilepsy syndrome Diseases 0.000 claims description 6
- 208000002877 Epileptic Syndromes Diseases 0.000 claims description 6
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 6
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 claims description 4
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 claims description 4
- 101000684820 Homo sapiens Sodium channel protein type 3 subunit alpha Proteins 0.000 claims description 4
- 101000654381 Homo sapiens Sodium channel protein type 8 subunit alpha Proteins 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 206010061334 Partial seizures Diseases 0.000 claims description 4
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 claims description 4
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 claims description 4
- 102100023720 Sodium channel protein type 3 subunit alpha Human genes 0.000 claims description 4
- 102100031371 Sodium channel protein type 8 subunit alpha Human genes 0.000 claims description 4
- 201000007186 focal epilepsy Diseases 0.000 claims description 4
- 230000000926 neurological effect Effects 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 claims description 2
- 208000002091 Febrile Seizures Diseases 0.000 claims description 2
- 208000003078 Generalized Epilepsy Diseases 0.000 claims description 2
- 101000944018 Homo sapiens Potassium channel subfamily T member 1 Proteins 0.000 claims description 2
- 208000035899 Infantile spasms syndrome Diseases 0.000 claims description 2
- 102000005453 KCNQ2 Potassium Channel Human genes 0.000 claims description 2
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims description 2
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims description 2
- 208000037158 Partial Epilepsies Diseases 0.000 claims description 2
- 102100033508 Potassium channel subfamily T member 1 Human genes 0.000 claims description 2
- 206010071141 Rasmussen encephalitis Diseases 0.000 claims description 2
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 claims description 2
- 108010052164 Sodium Channels Proteins 0.000 claims description 2
- 102000018674 Sodium Channels Human genes 0.000 claims description 2
- 208000023944 Sudden Unexpected Death in Epilepsy Diseases 0.000 claims description 2
- 208000008233 autosomal dominant nocturnal frontal lobe epilepsy Diseases 0.000 claims description 2
- 208000017888 childhood-onset epilepsy syndrome Diseases 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 230000001617 migratory effect Effects 0.000 claims description 2
- -1 CH 3 Chemical group 0.000 claims 1
- 206010053398 Clonic convulsion Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000336A JP2024019735A (ja) | 2018-09-28 | 2024-01-04 | イオンチャネルモジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738508P | 2018-09-28 | 2018-09-28 | |
| US62/738,508 | 2018-09-28 | ||
| PCT/US2019/053467 WO2020069322A1 (en) | 2018-09-28 | 2019-09-27 | Ion channel modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000336A Division JP2024019735A (ja) | 2018-09-28 | 2024-01-04 | イオンチャネルモジュレーター |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022502442A JP2022502442A (ja) | 2022-01-11 |
| JP2022502442A5 JP2022502442A5 (https=) | 2022-10-05 |
| JPWO2020069322A5 true JPWO2020069322A5 (https=) | 2022-10-05 |
| JP7576539B2 JP7576539B2 (ja) | 2024-10-31 |
Family
ID=69949703
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517348A Active JP7576539B2 (ja) | 2018-09-28 | 2019-09-27 | イオンチャネルモジュレーター |
| JP2024000336A Pending JP2024019735A (ja) | 2018-09-28 | 2024-01-04 | イオンチャネルモジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000336A Pending JP2024019735A (ja) | 2018-09-28 | 2024-01-04 | イオンチャネルモジュレーター |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12479844B2 (https=) |
| EP (1) | EP3856193A4 (https=) |
| JP (2) | JP7576539B2 (https=) |
| KR (1) | KR102842377B1 (https=) |
| CN (1) | CN113573713A (https=) |
| AU (2) | AU2019346635A1 (https=) |
| BR (1) | BR112021005913A2 (https=) |
| CA (1) | CA3142470A1 (https=) |
| EA (2) | EA202092908A1 (https=) |
| IL (1) | IL281946A (https=) |
| MX (1) | MX2021003634A (https=) |
| WO (1) | WO2020069322A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
| WO2019232209A1 (en) | 2018-05-30 | 2019-12-05 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| US12552797B2 (en) | 2019-11-27 | 2026-02-17 | Praxis Precision Medicines, Inc. | Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine |
| US20250145637A1 (en) | 2021-08-10 | 2025-05-08 | Jiangsu Hengrui Pharmaceuticals Co. Ltd. | Sulfonamide derivative, preparation method therefor and medical use thereof |
| MX2024013240A (es) | 2022-04-26 | 2024-12-06 | Praxis Prec Medicines Inc | Tratamiento de trastornos neurologicos |
| WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
| KR20250173086A (ko) | 2024-05-31 | 2025-12-10 | 더웨이브컨설팅 주식회사 | 이온 채널 조절 활성을 갖는 반도비탈거미 유래 펩타이드 및 이의 용도 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4230705A (en) | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
| CA1080712A (en) | 1976-09-22 | 1980-07-01 | Jay D. Albright | Hypotensive agents |
| US4112095A (en) | 1976-10-07 | 1978-09-05 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents |
| US4242515A (en) | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| GB9507348D0 (en) | 1995-04-08 | 1995-05-31 | Knoll Ag | Therapeutic agents |
| WO2002006286A2 (en) | 2000-07-14 | 2002-01-24 | Bristol-Myers Squibb Pharma Company | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| WO2006061428A2 (en) | 2004-12-10 | 2006-06-15 | Universität Zürich | Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain |
| US20100088778A1 (en) | 2005-06-16 | 2010-04-08 | John Charles Mulley | Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene |
| HUE030390T2 (en) | 2005-12-21 | 2017-05-29 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| KR100858357B1 (ko) | 2006-10-02 | 2008-09-11 | (주) 디지탈바이오텍 | 벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물 |
| FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| CA2713521A1 (en) | 2008-02-06 | 2009-08-13 | Gilead Palo Alto, Inc. | Use of ranolazine for treating pain |
| WO2010053757A1 (en) | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| WO2010074807A1 (en) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
| US20100125091A1 (en) | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds as ion channel modulators |
| JP5657566B2 (ja) | 2008-12-24 | 2015-01-21 | バイアル ポルテラ アンド シーエイ エス エイＢＩＡＬ−Ｐｏｒｔｅｌａ ＆ Ｃａ， Ｓ．Ａ． | 医薬品 |
| CN102439008B (zh) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途 |
| US8952034B2 (en) | 2009-07-27 | 2015-02-10 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2011056985A2 (en) | 2009-11-04 | 2011-05-12 | Gilead Sciences, Inc. | Substituted heterocyclic compounds |
| FR2953520B1 (fr) | 2009-12-04 | 2011-11-25 | Sanofi Aventis | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
| WO2012065297A1 (en) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| US9139576B2 (en) | 2011-05-03 | 2015-09-22 | Merck Sharp & Dohme Corp. | Aminomethyl biaryl benzotriazole derivatives |
| CA2834164A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused benzoxazinones as ion channel modulators |
| NO3175985T3 (https=) | 2011-07-01 | 2018-04-28 | ||
| CA2849505A1 (en) | 2011-09-21 | 2013-03-28 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| US9586963B2 (en) | 2011-09-27 | 2017-03-07 | Genfit | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists |
| JP2016511744A (ja) | 2012-12-21 | 2016-04-21 | エピザイム，インコーポレイティド | Ｐｒｍｔ５を阻害する方法 |
| US20140329755A1 (en) | 2013-05-01 | 2014-11-06 | Gilead Sciences, Inc. | Combination therapy for the treatment of arrhythmias or heart failure |
| CA2915838C (en) | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| DK3035926T3 (da) | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| GB201321740D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| AU2014364783B2 (en) | 2013-12-19 | 2017-01-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2015157955A1 (en) | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| ES2912073T3 (es) | 2014-06-20 | 2022-05-24 | Mitsubishi Chem Corp | Policarbonatodiol, método para producir el mismo, y poliuretano producido usando el mismo |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| KR101819433B1 (ko) | 2014-06-26 | 2018-01-16 | 에프. 호프만-라 로슈 아게 | 인돌린-2-온 또는 피롤로-피리딘-2-온 유도체 |
| JP2017001991A (ja) | 2015-06-11 | 2017-01-05 | 大日本住友製薬株式会社 | 新規ベンズオキサゾロン化合物 |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| US20210188839A1 (en) | 2016-11-28 | 2021-06-24 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
| EA201991306A1 (ru) | 2017-08-30 | 2020-03-20 | Праксис Пресижн Медсинз, Инк. | Соединения и способы их применения |
| WO2019232209A1 (en) | 2018-05-30 | 2019-12-05 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| EP4065124A4 (en) | 2019-11-26 | 2023-12-06 | Praxis Precision Medicines, Inc. | ION CHANNEL MODULATORS |
| US12552797B2 (en) | 2019-11-27 | 2026-02-17 | Praxis Precision Medicines, Inc. | Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine |
-
2019
- 2019-05-30 EA EA202092908A patent/EA202092908A1/ru unknown
- 2019-09-27 EA EA202190879A patent/EA202190879A1/ru unknown
- 2019-09-27 US US17/280,485 patent/US12479844B2/en active Active
- 2019-09-27 JP JP2021517348A patent/JP7576539B2/ja active Active
- 2019-09-27 CA CA3142470A patent/CA3142470A1/en active Pending
- 2019-09-27 EP EP19865432.9A patent/EP3856193A4/en active Pending
- 2019-09-27 WO PCT/US2019/053467 patent/WO2020069322A1/en not_active Ceased
- 2019-09-27 CN CN201980078653.2A patent/CN113573713A/zh active Pending
- 2019-09-27 MX MX2021003634A patent/MX2021003634A/es unknown
- 2019-09-27 AU AU2019346635A patent/AU2019346635A1/en not_active Abandoned
- 2019-09-27 BR BR112021005913-0A patent/BR112021005913A2/pt unknown
- 2019-09-27 KR KR1020217012574A patent/KR102842377B1/ko active Active
-
2021
- 2021-03-31 IL IL281946A patent/IL281946A/en unknown
-
2024
- 2024-01-04 JP JP2024000336A patent/JP2024019735A/ja active Pending
-
2025
- 2025-05-29 AU AU2025204027A patent/AU2025204027A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024019735A5 (https=) | ||
| JP2022502442A5 (https=) | ||
| JPWO2020069322A5 (https=) | ||
| JP2023144130A5 (https=) | ||
| JP2021525800A5 (https=) | ||
| RU2004117545A (ru) | Аминопиримидины и пиридины | |
| JP2009536620A5 (https=) | ||
| JP2003519676A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| JP2015522036A5 (https=) | ||
| JP2018501253A5 (https=) | ||
| JPWO2020079198A5 (https=) | ||
| JP2014532716A5 (https=) | ||
| JP2006507355A5 (https=) | ||
| RU97112090A (ru) | Фунгицидная смесь | |
| RU2018123714A (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| RU2005125919A (ru) | Альфа-аминоамидные производные, применимые в качестве антимигренозных средств | |
| RU2001111323A (ru) | Производные 2-фенилпиран-4-она | |
| JP6184866B2 (ja) | 新規抗がん剤 | |
| CA2523253A1 (en) | Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists | |
| JPWO2021195066A5 (https=) | ||
| CN107531634A (zh) | 作为wnt信号通路抑制剂的3‑氨基甲酰基苯基‑4‑甲酰胺和间苯二甲酰胺衍生物 | |
| JPWO2020033488A5 (https=) | ||
| RU2006117631A (ru) | Антагонисты рецептора ссr3 | |
| BR8801785A (pt) | Processo para producao de compostos,composicoes inseticidas ou acaricidas,aplicacao de tais compostos e processo para o combate de insetos e acaricios |